NCT04091451 - Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster | Biotech Hunter

Enrollment

1,430

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)

2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.

DRUG

Placebo

2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.

Trial Locations (44)

1001

GSK Investigational Site, Panama City

13619

GSK Investigational Site, Tallinn

20100

GSK Investigational Site, Turku

28035

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Madrid

34000

GSK Investigational Site, Durango

40100

GSK Investigational Site, Jyväskylä

44638

GSK Investigational Site, Guadalajara

46020

GSK Investigational Site, Valencia

50106

GSK Investigational Site, Tartu

68000

GSK Investigational Site, Oaxaca City

70100

GSK Investigational Site, Kuopio

115478

GSK Investigational Site, Moscow

188300

GSK Investigational Site, Gatchina

197022

GSK Investigational Site, Saint Petersburg

620137

GSK Investigational Site, Yekaterinburg

656043

GSK Investigational Site, Barnaul

00180

GSK Investigational Site, Helsinki

00290

GSK Investigational Site, Helsinki

FI-33100

GSK Investigational Site, Tampere

000000

GSK Investigational Site, Pokfulam

GSK Investigational Site, Shatin

06760

GSK Investigational Site, Mexico City

0801

GSK Investigational Site, Panama City